They need a positive response from the grant requests they've made, as this will provide cash flow and reduce their need to keep issuing stock to Fusion Capital.
Still, without any grant money, they've got another $3 million plus of money left with their Fusion agreement and assuming at worst case that it is all raised at the current 20 cents/share, that is an additional 15 million shares outstanding, or 41 million in total. Even with 41 million outstanding some day in the future, at 20 cents this is only an $8 million market cap.
The technology appears to work and appears safe per the Indian trials--still, they need some positive repsonse from the FDA in the U.S.
I like the CEO and believe he and the Board are committed to success here.
I agree this could be a mega homerun. When the avian flu scare returns, or there is a bioterror incident, this stock will move on speculation alone.